9.47
Jade Biosciences Inc stock is traded at $9.47, with a volume of 168.36K.
It is down -3.37% in the last 24 hours and up +6.88% over the past month.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$9.80
Open:
$9.94
24h Volume:
168.36K
Relative Volume:
1.32
Market Cap:
$308.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.07%
1M Performance:
+6.88%
6M Performance:
-24.12%
1Y Performance:
+0.00%
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare JBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
JBIO
Jade Biosciences Inc
|
9.47 | 450.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
How Jade Biosciences Inc. stock reacts to Fed rate cutsBull Run & Weekly High Potential Stock Alerts - newser.com
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Will Jade Biosciences Inc. see short term momentumMarket Growth Review & Low Risk Entry Point Tips - newser.com
Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jade Biosciences (NASDAQ:JBIO) Receives "Sell (E)" Rating from Weiss Ratings - MarketBeat
How Jade Biosciences Inc. stock reacts to inflationary pressures2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
How Jade Biosciences Inc. stock performs during Fed tightening cyclesWeekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
Is Jade Biosciences Inc. stock positioned for long term growthQuarterly Profit Review & Low Risk High Win Rate Stock Picks - newser.com
Will Jade Biosciences Inc. stock see PE expansionWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Is Jade Biosciences Inc. forming a reversal pattern2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Jade Biosciences Advances with Phase 1 Study of JADE101 - TipRanks
Jade Biosciences (JBIO) Price Target Increased by 13.43% to 19.38 - Nasdaq
Will Jade Biosciences Inc. stock keep outperforming rivals2025 Key Lessons & Real-Time Chart Pattern Alerts - fcp.pa.gov.br
Multi asset correlation models including Jade Biosciences Inc.Earnings Performance Report & Capital Efficiency Focused Ideas - newser.com
What technical charts say about Jade Biosciences Inc. stockJuly 2025 Analyst Calls & Weekly High Conviction Ideas - fcp.pa.gov.br
Aug Summary: Will Jade Biosciences Inc. stock benefit from automationQuarterly Performance Summary & Community Driven Trade Alerts - fcp.pa.gov.br
Jade Biosciences Inc Stock (JBIO) Financials Data
There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):